Support for your GLP-1 journey While digestive side effects can be uncomfortable at-first, they are usually temporary and manageable
If you have started a new exercise plan with weights, you might be building strong, healthy muscle
Results may not apply to all individuals
Both drugs are being developed by Novo Nordisk, likely reflecting a portfolio strategy: CagriSema as the first-to-market injectable combination, and amycretin as a follow-on oral option for patients who prefer pills
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers
Liu SH, Shi XJ, Fan FC, Cheng Y (2021) Peripheral blood neurotrophic factor levels in children with Autism Spectrum Disorder: a meta-analysis